

DEPARTMENT OF VETERANS AFFAIRS

**Justification and Approval
For
Other Than Full and Open Competition (>\$150K)**

Acquisition Plan Action ID: VA260-17-AP-0864

1. **Contracting Activity:** Department of Veterans Affairs, VISN 20, Portland VA Medical Center (PVAMC).

2. **Nature and/or Description of the Action Being Processed:**

This requirement will be funded by purchase request number PR # 648-17-3-066-0063.

This is a request for other than full and open competition for reference laboratory services with professional interpretation of test results performed in the reference lab, all in support of direct patient care.

3. **Description of Supplies or Services Required to Meet the Agency's Needs:**

The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, coagulation and cancer testing and interpretation for the tests listed in the table below. Reference lab will provide the test results to Portland Pathology & Laboratory (PLMS), PVAMC.

Work will be performed in the Oregon Health & Science University (OHSU) Reference Laboratory,

The proposed contractor is Oregon Health & Science University, and the total estimated value of the proposed action is \$8,915,259.73 over a five-year period with the base period beginning on 02-01-2017 and running to 09-30-2017. The base period is estimated at \$1,273,608.53, and the four option years total \$7,641,651.20.

Description	CPT	Est. Quantity 0.5 Year	Est. Quantity Full Year	Program
Molecular diagnosis: Cancer Interpretation and report	83912	67	134	Cancer Interpretation
Molecular diagnosis: Cancer Interpretation and report	83912	67	134	Cancer Interpretation
Molecular diagnosis: Cancer Interpretation and report	83912	66	132	Cancer Interpretation
Blood Smear peripheral Cancer Interpretation with report	85060	150	300	Cancer Interpretation
Bone marrow smear Cancer Interpretation, with or without differential cell count	85097	170	340	Cancer Interpretation
Cytopathology, concentration technique, smears and Cancer Interpretation	88108	175	350	Cancer Interpretation
flow cytometry, Cancer Interpretation; 2-8 markers	88187	150	300	Cancer Interpretation
flow cytometry, Cancer Interpretation; 9-15 markers	88188	150	300	Cancer Interpretation
flow cytometry, Cancer Interpretation; 16 or more markers	88189	150	300	Cancer Interpretation
Cytogenetics and molecular cytogenetics, Cancer Interpretation and report	88291	150	300	Cancer Interpretation
Level IV surgical pathology, gross and microscopic examination	88305	150	300	Cancer Interpretation
Special Stains, group II	88313	149	298	Cancer Interpretation
Special Stains, histochemical staining with frozen sections	88314	150	300	Cancer Interpretation
Determinative histochemistry or cytochemistry to identify enzyme constituents	88319	150	300	Cancer Interpretation
Consultation and report on referred slides prepared elsewhere	88321	162	324	Cancer Interpretation
immunocytochemistry (including immunoperoxidase) each antibody	88342	188	376	Cancer Interpretation
Immunofluorescent study, each antibody, direct method	88346	200	400	Cancer Interpretation
Electron microscopy, diagnostic	88348	200	400	Cancer Interpretation
Morphometric analysis, in situ hybridization	88368	200	400	Cancer Interpretation

Macroscopic examination, dissection, and preparation of tissue for non-microscopic analytical studies (nucleic acid-based molecular studies)	88387	200	400	Cancer Interpretation
ABL SEQ MOLE SEP BY CAP ELE	81403	70	140	Cancer Testing
Addl Karyotype simple	88280	75	150	Cancer Testing
ANTI-B2-GLYCOPROTIEN ICG	86146	70	140	Coagulation Testing
ANTICARDIOLIPIN IGG or IGM	86147	70	140	Coagulation Testing
ANTITHROMBIN ACTIVITY	85300	70	140	Coagulation Testing
APTT 1"1 MIX 0 MIN	85732	70.5	141	Coagulation Testing
APTT PLASMA 60 MIN	85730	70	140	Coagulation Testing
BCR/ABL FISH Probe	88271	68	136	Cancer Testing
BCR-ABL Nested PCR Assay	81208	70	140	Cancer Testing
BCR-ABL RNA Major Breakpoint	81206	70	140	Cancer Testing
BCR-ABL RNA Minor Breakpoint	81207	70	140	Cancer Testing
Bone Marrow Chromosome	88237	81.5	163	Cancer Testing
Butyrate Esterase Stain	88319	70	140	Cancer Testing
CNT 15-20 cells 2 karyotype	88262	70	140	Cancer Testing
DECALIFICATION	88311	70	140	Cancer Testing
DVV confirm ratio	85613	70	140	Coagulation Testing
DVVT	85613	70	140	Coagulation Testing
EOSINOPHILS Fish Probe	88271	70	140	Cancer Testing
FACTOR II ACTIVITY	85210	70	140	Coagulation Testing
FACTOR IX ACTIVITY	85250	70	140	Coagulation Testing
Factor V Activity	85220	70	140	Coagulation Testing
Factor V inhibitor	85335	70	140	Coagulation Testing
Factor VII Activity	85230	70	140	Coagulation Testing
FACTOR VIII COAG ACTIVITY	85240	70	140	Coagulation Testing
FACTOR VIII VWF AG	85246	70	140	Coagulation Testing
FACTOR X CHROMOGENIC	85260	70	140	Coagulation Testing
FACTOR XI ACTIVITY	85270	70	140	Coagulation Testing
FACTOR XII ACTIVITY	85280	70	140	Coagulation Testing
FACTOR XIII QUAL	85290	70	140	Coagulation Testing
Hem onc bld chromo	88237	70	140	Cancer Testing
HEPARIN EITHER STD/LMW	85520	70	140	Coagulation Testing
HEPARIN PLT AB LUMI AGG	86022	75	150	Coagulation Testing
HEXAGONAL PL APTT	85598	70.5	141	Coagulation Testing
Hormone Receptors, ER, PR, EA	88360	75	150	Cancer Testing
IMMUNOFLUORESCENCE (EA)	88346	20	40	Cancer Testing
IMMUNOHISTOCHEMISTRY	88342	55	110	Cancer Testing
IN SITU HYBRIDIZATION	88368	75	150	Cancer Testing
interphase 100-300 cells	88275	80	160	Cancer Testing
JAK2 V617F Qual Mut Analysis	81270	70	140	Cancer Testing
JAK2 V617F Quant Mut Analysis	81270	70	140	Cancer Testing
METHOTREXATE	80299	75	150	Cancer Testing
molecular probe	88271	70	140	Cancer Testing

MSI MULTIPLEX PCR	81301	75	150	Cancer Testing
MSI MULTIPLEX PCR 1ST 2	81301	75	150	Cancer Testing
MYELOPEROXIDASE STAIN	88319	67.5	135	Cancer Testing
PLATELET FACTOR 4 W/REFLEX TO HAL	86022	56.5	113	Coagulation Testing
Platelet Function Analysis	85576	56.5	113	Coagulation Testing
RETICULATED PLATELETS	85046	32.5	65	Cancer Testing
SPECIAL STAIN OTHER	88313	32.5	65	Cancer Testing
SUDAN BLACK B STAIN LEUKOCYTE	88313	32.5	65	Cancer Testing
SURFACE MARKER AB ADDL	88184	32.5	65	Cancer Testing
SURFACE MARKER AB FIRST	88185	32	64	Cancer Testing
T CELL QUANT (T,B AND NK)	86360	32.5	65	Cancer Testing
VONWILL/RAF	85245	56.5	113	Coagulation Testing

5. Statutory Authority Permitting Restriction in Competition:

The authority for restricting competition on this procurement is under 41 U.S.C. Code 3304(a), as implemented by FAR 6.302.

Per FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.

6. Demonstration that the Contractor's Unique Qualifications or Nature of the Acquisition Requires the Use of the Authority Cited Above (applicability of authority):

A review of the potential acquisition alternatives was performed taking into consideration previous acquisitions of a similar item or service, the impact of prior acquisitions on these alternatives, and related in-house efforts, which indicated that the best acquisition method was identified.

In-house resources, or the award of a new contract based on full and open competition after the exclusion of sources were both considered for this requirement. The PVAMC does not have the resources available to perform this service on their own, nor does it employ the required personnel to fill this need. As such, the facility requires testing and interpretation services from a reference laboratory that will be able to initiate specimen processing within 1 hour of specimen collection for all tests listed in the "program" Coagulation Testing, because coagulation and blood clotting disorders require immediate treatment and management. Patients are waiting for scheduled surgery or changes to medication doses.

There are several contractors that are capable of providing the required coagulation and cancer testing; however OHSU is the only contractor that could be found that is capable of providing this one hour testing start time requirement. There is a sky bridge that connects PVAMC with OHSU.

Delays in treatment and management of coagulation and blood clotting disorders are unacceptable for the prompt access of the VA, whereas immediate testing and resulting through a reference laboratory able to meet the 1 hour processing standard, furthers the goal of timely patient access. Delays in test results beyond 4-12 hours would typically result in canceled/delayed surgeries/treatments or serious negative consequences for patients with high risk factors (cancer, cardiovascular disease and serious health conditions).

The expected turn-around time for coagulation tests results related to surgical procedures must be within 8 hours.

7. Description of Efforts Made to Ensure that Offers are Solicited from As Many Potential Sources as Deemed Practicable:

Competition was sought for this requirement by posting a sources sought notice to FedBizOpps and to GSA e-Buy on 11-03-2016 with a closing date of 11-10-2016. GSA lists five Medical Laboratories, four of which are large business, and one of which is a small business (Cedar Diagnostics).

The only businesses that could be found that showed any interest in this requirement was from the sources sought notice posted to GSA. Quest Diagnostics provided a capabilities statement, but stated they could not meet the testing start time of one hour after specimen collection. Cedar Diagnostics also provided a capabilities statement, but stated they could not meet the testing start time of one hour after specimen collection. Cedar challenged the one-hour requirement, and stated that it is not required. However, it is the PVAMC laboratory's medical opinion that the one hour test start time for the coagulation and cancer tests is required and professionally disagree with Cedar's claims.

PVAMC stated in a meeting with the Contract Specialist on 11-08-16 that they are standing behind the one-hour testing requirement.

A review of services available from the Committee for Purchase from people who are blind or severely disabled (AbilityOne) showed this service could not be provided by from this source at this time.

Research was conducted by searching the UNICOR website and reviewing the online FPI Schedule. UNICOR does not offer these services.

Research was conducted by reviewing the online WSNC and VISN contracting vehicle listings. There was no BPA available for OHSU.

Vets First does not apply. However, for market research purposes, VetBiz was reviewed using NAICS code 621511 for Washington and Oregon and revealed 6 matches. A review of their capabilities statements revealed that none can provide the specific services needed.

8. Determination by the Contracting Officer that the Anticipated Cost to the Government will be Fair and Reasonable:

The anticipated cost will be considered to be fair and reasonable based upon a comparison of proposed prices with prices to historical prices paid IAW FAR 15.404-1(b) (2) (ii). In addition, the vendor's prices will also be compared to the Independent Government Estimate IAW FAR 15.404-1(b) (2) (v), which was developed independently.

9. Description of the Market Research Conducted and the Results, or Statement of Reasons Market Research was not Conducted (FAR 10):

As described in paragraph six above, market research, in accordance with FAR Part 10, was

conducted by posting a sources sought notice to FedBizOpps and to GSA on 11-03-16.

In addition, AbilityOne and UNICOR were checked, and they cannot provide the required services.

Based upon the above information, there is a high level of confidence that no other qualified sources exist.

10. Any Other Facts Supporting the Restriction of Competition:

Laboratory Corporation of America and Cedar Diagnostics hold a single award VISN 20 Blanket Purchase Agreements (BPA) for reference lab testing. In the event the one hour testing start time is changed, their BPAs could be used.

11. Listing of Sources that Expressed, in Writing, an Interest in the Acquisition:

As stated in paragraph 6, Competition was sought for this requirement by posting a sources sought notice to FedBizOpps and to GSA e-Buy on 11-03-2016 with a closing date of 11-10-2016. The sources sought number is VA260-17-N-0033.

Quest Diagnostics provided a capabilities statement, but stated they could not meet the testing start time of one hour after specimen collection. Cedar Diagnostics also provided a capabilities statement, but stated they could not meet the testing start time of one hour after specimen collection. Cedar challenged the one-hour requirement, and stated that it is not required. However, it is the PVAMC laboratory's medical opinion that the one hour test start time for the coagulation and cancer tests, is required and professionally disagree with Cedar's claims.

12. Statement of Actions, if any, the Agency May Take to Remove or Overcome any Barriers to Competition before Making Subsequent Acquisitions for the Supplies or Services Required:


A sources sought notice was posted to FedBizOpps and to GSA to determine if other interested concerns have the ability to furnish these services. A capability statement was requested in the notice.

In the event new or unknown medical evidence changes the professional medical opinion of the PVAMC laboratory, regarding specimen testing beginning within one hour of collection, this requirement may be able to be competed if the specimen testing start time is extended from one hour to a time long enough for other laboratories located elsewhere in the country to be able to provide the required reference laboratory services.

PVAMC will continue to perform on going market research for other US labs acquiring the capabilities to perform these unique and challenging tests.

13. Requirements Certification:

I certify that the requirement outlined in this justification is a bonafide need of the Department of Veterans Affairs and that the supporting data under my cognizance, which are included in the justification, are accurate and complete to the best of my knowledge and belief.



Name: SUZANNE M. DENKER
Administrative Officer
Portland VA Medical Center

Date: 12/2/2016

14. Approvals in accordance with the VHAPM, Volume 6, Chapter VI: OFOC SOP:

- a. **Contracting Officer's Certification: (required)** I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief.

Thomas M. Ebenhoh 996911

Digitally signed by Thomas M. Ebenhoh 996911
DN: dc=gov, dc=va, o=internal, ou=people,
0.9.2342.19200300.100.1.1=thomas.ebenhoh@va.gov, cn=Thomas M.
Ebenhoh 996911
Date: 2016.12.05 07:29:38 -08'00'

Name: THOMAS M. EBENHOH
Contracting Officer
Network Contracting Office 20 (NCO 20)

Date: 5 December 2016

- b. **Director of Contracting:** I certify the justification meets requirements for other than full and open competition.

Scott I. Benza
1119730

Digitally signed by Scott I. Benza 1119730
DN: dc=gov, dc=va, o=internal, ou=people,
0.9.2342.19200300.100.1.1=scott.benza@va.gov, cn=Scott I. Benza 1119730
Date: 2016.12.05 11:53:42 -08'00'

SCOTT I. BENZA
Director of Contracting
Network Contracting Office 20 (NCO 20)

5 Dec 2016
Date

- c. **HCA Review and Approval:** I have reviewed the foregoing justification and find it to be complete and accurate to the best of my knowledge and belief and approve for other than full and open competition.

Delia A.
Adams 196519

Digitally signed by Delia A. Adams
196519
DN: dc=gov, dc=va, o=internal,
ou=people,
0.9.2342.19200300.100.1.1=delia.adams
@va.gov, cn=Delia A. Adams 196519
Date: 2016.12.13 12:32:44 -08'00'

DELIA A. ADAMS, MBA, CPCM
Director, SAO West
Head of Contracting Activity (HCA)

13 December 16
Date

ADDENDED SCHEDULE

Line Item	Proc Code Description	OHSU CPT	Estimated Annual Tests
	CANCER TESTING:		
0001	HB-LAB ANTICARDIOLIPIN IGG or IGM	86147	70
0002	ANTITHROMBIN ACTIVITY	85300	70
0003	APTT 1"1 MIX 0 MIN	85732	80
0004	APTT PLASMA 60 MIN	85730	80
0005	BCR/ABL +1 ASS t(9:22)	88271	20
0006	BCR-ABL RNA Quantitation, PCR	81206	80
0007	Bone Marrow Chromosome	88237, 88280, 88262	100
0008	Butyrate Esterase Stain	88319	10
0009	DECALIFICATION	88311	120
0010	DVV confirm ratio	85613	80
0011	DVVT	85613	100
0012	Hyper eosinophilia Panel	88271x3, 88275x3	5
0013	FACTOR II ACTIVITY	85210	5
0014	FACTOR IX ACTIVITY	85250	5
0015	Factor V Activity	85220	100
0016	Factor V inhibitor	85335	5
0017	Factor VII Activity	85230	5
0018	FACTOR VIII COAG ACTIVITY	85240	50
0020	FACTOR VIII VWF AG	85246	50
0021	FACTOR X CHROMOGENIC	85260	100
0022	FACTOR XI ACTIVITY	85270	5
0023	FACTOR XII ACTIVITY	85280	5
0024	FACTOR XIII QUAL	85290	5
0025	Hem/Onc Blood Chromosome Analysis	88237, 88280, 88262	5
0026	HEPARIN EITHER STD/LMW	85220	30
0027	HEPARIN PLT AB LUMI AGG	86022	40
0028	HEXAGONAL PL APTT	85598	100
0029	Hormone Receptors, ER, PR, EA	88360	20
0030	IMMUNOFLUORESCENCE (EA)	88346	200
0031	IMMUNOHISTOCHEMISTRY	88342	350
0032	IN SITU HYBRIDIZATION	88368	100
0033	METHOTREXATE	80299	40
0034	MSI MULTIPLEX PCR	81301	15
0035	MSI MULTIPLEX PCR 1ST 2	81310	15
0036	MYELOPEROXIDASE STAIN	88319	10
0037	PLATELET FACTOR 4 W/REFLEX TO HAL	86022	40
0038	Platelet Function Analysis	85576	20
0039	RETICULATED PLATELETS	85046	40
0040	SPECIAL STAIN OTHER	88313	40
0041	SUDAN BLACK B STAIN LEUKOCYTE	88313	20
0042	SURFACE MARKER AB ADDL	88184	5500
0043	SURFACE MARKER AB FIRST	88185	400
0044	T CELL QUANT (T,B AND NK)	86360	20
0045	VONWILL/RAF (85245)	85245	40
0046	ALK (2p23) (FFPE)	8019	40

ADDENDED SCHEDULE

0047	ALK Mutation Analysis	4023	2
0048	ALL PANEL	7010	5
0049	AML PANEL	7014	12
0050	AML PANEL (FFPE)	7014	8
0051	APOL1 Gene Sequencing	1050	2
0052	B-Cell (IgH and Ig-kappa) Gene Rearrangement (Clonality)	4070	15
0053	BCL2 (18q21.3)	8040	10
0054	BCL6 (3q27) (FFPE)	8050	10
0055	BCR-ABL Kinase Domain Mutations (Sequencing)	4020	8
0056	Blood: High Resolution Chromosome Study reflexed to	6054	5
0057	BRAF Mutation Analysis (exon 15)	4110	25
0058	Calreticulin (CALR)	4140	30
0059	CCND1 (11q13)	8115	3
0060	CEBPA Mutation Analysis	4150	3
0061	CHIC2 (4q11)	8090	3
0062	cKIT for AML (exon 8,17)	4206	3
0063	cKIT for MASTOCYTOSIS, High Sensitivity (exon 17)	4208	3
0064	CKIT for MUTATION ANALYSIS (exons 11,13,17)	4210	3
0065	CLL/SLL PANEL	7100	20
0066	DIFFUSE LARGE B-CELL LYMPHOMA PANEL	7450	20
0067	DIFFUSE LARGE B-CELL LYMPHOMA PANEL (FFPE)	7450	20
0068	EGFR (7p12)/CEN7 (FFPE)	8180	20
0069	ETV6/RUNX1 t(12;21) (TEL/AML1)	8794	5
0070	FGFR1 (8p21)	8218	3
0071	FLT3 ITD Mutation	4460	3
0072	GeneTrails AML/MDS Genotype Panel (42 Gene Panel)	4025	15
0073	GeneTrails Colon Mutation Panel (KRAS,BRAF, NRAS)	4224	15
0074	GeneTrails Hematologic Malignancies 76 Gene Panel	4600	6
0075	Glioma Panel	7270	15
0076	IDH1 & IDH2 Mutation Analysis	4650	15
0077	IGH/BCL2 t(14;18)	7360	8
0078	IGH/BCL2 t(14;18) (FFPE)	7360	8
0079	IGH/CCND1 t(11;14)	7090	8
0080	IGH/MYC t(8;14)	8342	8
0081	JAK2 Exon 12 Mutation Analysis	4736	15
0082	JAK2 V617F Quant Mut Analysis (81270)	4734	75
0083	JAK2 V617 Mutation, Quantitative, w/reflex to Calreticulin	4740	5
0084	KRAS Mutation Analysis (exon 1,2)	4800	15
0085	Marginal Zone Lymphoma Panel	7454	5
0086	MDS Panel	7500	15
0087	Melanoma Panel (BRAF, NRAS, cKIT Mutations)	4900	10
0088	MGMT Methylation	5005	5
0089	Microsatellite Instability (MSI)	5000	5
0090	MPL Mutation Analysis	5010	5
0091	Multiple Myeloma Panel	7520	20
0092	Multiple Myeloma Panel (FFPE)	7520	20
0093	NPM1 (Nucleophosmin) Mutation Analysis	5080	5
0094	NRAS Mutation Analysis (exon 1,2)	5100	5
0095	PML/RARA t(15;17)	8636	10
0096	PML-RARA Quantitative RT PCR	5300	10
0097	Post-Transplant Engraftment (Chimerism)	4388	2
0098	Post-Transplant, Sorted Cell Chimerism	4390	2

ADDENDED SCHEDULE

0099	PTEN (10q23)/CEN10) (FFPE)	8642	2
0100	PTEN IHC	5350	3
0101	ROS1 (6q22) (FFPE)	8720	3
0102	RUNX1/RUNX1T1 (aka AML/ETO) t(8;21)	8020	3
0103	Solid Tissue Tumor: Full Study	6810	3
0104	Solid Tissue/ Lymph Node	6460	3
0105	T and B Cell Gene Rearrangement (B-Cell IGH & IGK, T-Cell	5590	10
0106	T-Cell (TCR-gamma and TCR-beta) Gene Rearrangement	5592	10
0107	monospot	86308	15
0108	Alcohols, Differential	80320	10
0109	Ethylene glycol	82693	10
0110	Prep Surg Spec, Level IV	88305	40
0111	Electron Microscopy	88348	35
0112	Immunohistochemistry ADDL AB Stain (88341)	88341	50
0113	Immunofluorescence ADDL AB Stain (88350)	88350	50
0114	Anti-Retinal Ab, Western Blot		2
0115	Anti-Retinal Auto AB, IHC		2
0116	Anti-Optic Nerve AB, Western Blot		2
0117	Platelet Aggregation		5
0118	Hypersensitivity Pneumonitis		5
0119	Thrombin Time		5
0120	Paroxysmal Nocturnal Hemoglobinuria (PNH)		5
	CANCER INTERPRETATION:		
0121	Molecular diagnosis: Cancer Interpretation and report	G0452	100
0122	Molecular diagnosis: Cancer Interpretation and report	G0452	100
0123	Blood Smear peripheral Cancer Interpretation with report	G0452	100
0124	Bone marrow smear Cancer Interpretation, with or without differential cell	85060	5
0125	Cytopathology, concentration technique, smears and Cancer Interpretation	85097	25
0126	flow cytometry, Cancer Interpretation; 2-8 markers	88108	25
0127	flow cytometry, Cancer Interpretation; 9-15 markers	88187	40
0128	flow cytometry, Cancer Interpretation; 16 or more markers	88188	40
0129	Cytogenetics and molecular cytogenetics, Cancer Interpretation and report	88189	250
0130	Level IV surgical pathology, gross and microscopic examination	88291	250
0131	Special Stains, group II	88305	200
0132	Special Stains, histochemical staining with frozen sections	88313	80
0133	Determinative histochemistry or cytochemistry to identify enzyme constituents	88314	200
0134	Consultation and report on referred slides prepared elsewhere	88319	250
0135	immunocytochemistry (including immunoperoxidase) each antibody	88323	200
0136	Immunofluorescent study, each antibody, direct method	88341	250
0137	Electron microscopy, diagnostic	88350	150
0138	Morphometric analysis, in situ hybridization	88348	20
0139	Macroscopic examination, dissection, and preparation of tissue for non-	88368	100
0140	Molecular diagnosis: Cancer Interpretation and report	88381	100

ADDENDED SCHEDULE

Notes:

- 1 Testing must be able to start within 1 hour of draw and results within 8 hours.
- 2 Coagulation & platelet status must be monitored before during and after liver transplant and other surgeries to provide immediate adjustment to blood thinners or blood products on a 24/7 basis.
- 3 Coagulation and platelet function are critical life monitors for patients with liver diseases or other high risk factors (cancer, cardiovascular disease and serious health conditions)
- 4 Delays in test results beyond 4-12 hours would typically result in canceled/delayed surgeries/treatments or serious negative consequences for patients with high risk factors (cancer, cardiovascular disease and serious health conditions)
- 5 Test required establishing immediate update to dosage and treatment plan for blood clotting disorders or blood products.
- 6 Many specimens are fresh tissue requiring test processing to be initiated within 1 hour of collection to prevent specimen degradation which leads to unsatisfactory cell recovery or responses giving inconclusive or inadequate diagnoses resulting in delayed treatment with serious consequences for cancer patients.
- 7 Specimens are unique and irretrievable and aid in the diagnosis and staging of malignancies.
- 8 Required for STAT initial diagnosis and treatment initiation for leukemia and aggressive lymphoma.

ESTIMATED GRAND TOTAL FOR ALL FIVE PRICING YEARS: \$11,052,630.11